score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	MET	Amplification				0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				MET Amplification	0.0	MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.3664	131.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat174		
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.M598I	0.1628	43.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687													0				JAK3 p.M598I (Missense)	0.0	MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y236D	0.5217	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.Y236D (Missense)		MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D696N	0.2286	35.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0				AR p.D696N (Missense)		MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat174		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P949L	0.3069	101.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.P949L (Missense)	1.0	MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.L469F	0.2667	45.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH2 p.L469F (Missense)		MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.T1322S	0.3125	144.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.T1322S (Missense)		MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	MEL-IPI_Pat174-Normal-SM-5VWIY
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																					0				ATM Deletion		MEL-IPI_Pat174	MEL-IPI_Pat174-Tumor-SM-5VOB4	
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.808																									0				COSMIC Signature (version 2) 7 (81%)		MEL-IPI_Pat174		
